BACKGROUND

Currently available inhalers, including metered dose inhalers (MDIs), dry powder inhalers (DPIs) and nebulizers, are often less than effective in delivering the necessary medication.

The optimal delivery device strives for the most efficient and effective deposition of aerosol medication, taking into account drug particle/droplet size as well as the patient’s ability to understand and use the device.

Unfortunately, MDIs require hand-breath coordination. DPIs rely on breath actuation for dose release and may require forceful inhalation. Many patients do not use the device properly because of complexity. With nebulizers, treatment time is relatively long, setup is cumbersome, and the apparatus is usually bulky and inconvenient.  

The market needs an innovative aerosol delivery device that is convenient and easy to use; delivers the medication effectively; and suits adults, children, the elderly, and the seriously ill.

THE PRODUCT

Inspiro Medical is developing Inspiromatic™, a breakthrough DPI that uses advanced technology to overcome the drawbacks of current inhalers. Inspiro’s proprietary inhaler is the first device to combine an active dry powder fluidization mechanism that works with low inhalation flow rates combined with a unique real-time feedback control and data logger that indicates proper inhalation technique and follow-up. Inspiromatic assures optimal drug delivery.

See Inspiro CEO Nimrod Kaufmann present the Inspiromatic dry powder inhaler (YouTube).

Young children and the elderly will particularly benefit from the advantages of Inspiro’s dry powder inhalation.

THE MARKET

Inspiro’s unique DPI is developed for the treatment of pulmonary diseases such as asthma and chronic obstructive pulmonary disease (COPD). 

According to the World Health Organization, an estimated 300 million people worldwide suffer  from asthma, with 250,000 deaths attributed to the disease annually, and COPD affects 210 million people worldwide and is projected to be the third leading cause of death by 2020.